ArticleOncoTargets and therapy2016

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Edward B Garon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.